DRP1 LAtezolizumab | Durwalumab | Serplulimab + CTH 04/26 MESOTH.1 LNiwolumab+Ipilimumab 04/26 NDRP1 LAfatynib | Ozymertynib 04/26 NDRP1 LAmiwantamab + CTH 04/26 NDRP1 LAmiwantamab+Lazertynib 04/26 NDRP1 LAtezolizumab (unfit) 04/26 NDRP1 LAtezolizumab | Cemiplimab | Niwolumab+Ipilimumab | Pembrolizumab | Durwalumab+Tremelimumab ± CTH 04/26 NDRP1+ LAlektynib | Entrektynib | Kryzotynib | Lorlatynib 04/26 NDRP1+ LEnkorafenib+Binimetynib 04/26 NDRP2+ LAtezolizumab | Niwolumab | Tislelizumab 04/26 NDRP2+ LNintedanib + CTH 04/26 NDRP2+ LOzymertynib 04/26 NDRP2+ LSotorasib 04/26 NDRPADIUW.Alektynib 04/26 NDRPADIUW.Atezolizumab 04/26 NDRPADIUW.Ozymertynib 04/26 NDRPADIUW.Pembrolizumab 04/26 NDRPKONSOL.Durwalumab 04/26 NDRPKONSOLID.Ozymertynib 04/26 NDRPNEOAD.Niwolumab + CTH 04/26 NDRPOKOŁOOP.Pembrolizumab + CTH 04/26